XWELL (NASDAQ:XWEL – Get Free Report) and Aclarion (NASDAQ:ACON – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.
Profitability
This table compares XWELL and Aclarion’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| XWELL | -58.17% | -352.37% | -84.71% |
| Aclarion | -9,517.11% | -52.31% | -49.79% |
Institutional & Insider Ownership
8.7% of XWELL shares are owned by institutional investors. Comparatively, 7.5% of Aclarion shares are owned by institutional investors. 13.9% of XWELL shares are owned by insiders. Comparatively, 0.8% of Aclarion shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| XWELL | $29.21 million | 0.31 | -$16.99 million | ($5.11) | -0.22 |
| Aclarion | $80,000.00 | 92.91 | -$7.23 million | ($17.01) | -0.19 |
Aclarion has lower revenue, but higher earnings than XWELL. XWELL is trading at a lower price-to-earnings ratio than Aclarion, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
XWELL has a beta of 0.96, meaning that its stock price is 4% less volatile than the S&P 500. Comparatively, Aclarion has a beta of 1.13, meaning that its stock price is 13% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and target prices for XWELL and Aclarion, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| XWELL | 1 | 0 | 0 | 0 | 1.00 |
| Aclarion | 1 | 0 | 0 | 0 | 1.00 |
Summary
Aclarion beats XWELL on 6 of the 11 factors compared between the two stocks.
About XWELL
XWELL, Inc. provides health and wellness services in airport and off airport marketplaces in the United States and internationally. It operates in four segments: XpresSpa, XpresTest, Naples Wax Center, and Treat. The XpresSpa segment traveler's spa services, including massage, nail, and skin care services, as well as spa and travel products. The XpresTest segment offers diagnostic COVID-19 tests at XpresCheck Wellness Centers in airports, to airport employees and to the traveling public but has transitioned to the CDC's bio-surveillance program; and provides marketing support through HyperPointe business to various health and health-related channels. The Napple Wax Center segment offers skincare and cometic products, as well as face and body waxing services. The Treat segment provides access to wellness services for travelers at on-site centers, consisting of self-guided yoga, meditation, and low impact weight exercises programs. The company offers its services through stores, kiosks, and online. The company was formerly known as XpresSpa Group, Inc. and changed its name to XWELL, Inc. in October 2022. XWELL, Inc. is based in New York, New York.
About Aclarion
Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.
Receive News & Ratings for XWELL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XWELL and related companies with MarketBeat.com's FREE daily email newsletter.
